Ingersoll Rand (IR) Q2 2025: Backlog Climbs 16%, Bolstering M&A-Driven Growth Trajectory
Ingersoll Rand’s Q2 revealed a 16% backlog surge since year-end 2024, underlining robust demand visibility despite macro volatility. The company’s disciplined M&A flywheel added over $200 million in annualized revenue year-to-date, with integration and bolt-on strategies supporting both organic and inorganic growth. Management’s guidance raise and focus on recurring revenue, aftermarket expansion, and niche life sciences platforms point to resilient execution and a conservative, opportunity-rich outlook for the second half.
Summary
- Backlog Expansion Signals Demand Resilience: Elevated backlog and book-to-bill above one reinforce revenue visibility.
- M&A Flywheel Drives Diversification: Eleven acquisitions year-to-date expand technology and geographic reach.
- Guidance Raised on Execution and Capital Deployment: Management leans into bolt-ons, recurring revenue, and disciplined integration.
Performance Analysis
Ingersoll Rand’s Q2 performance revealed a business balancing macro uncertainty with internal momentum, as backlog increased by 16% since the end of 2024 and book-to-bill remained above one. Orders grew 8% YoY, and revenue gains were supported by both organic and M&A contributions, though adjusted EBITDA margin compressed to 27%—primarily due to lower organic volumes, the dilutive effect of recent acquisitions, and targeted growth investments. Aftermarket revenue rose to 37% of total, up 100 basis points YoY, reflecting a deliberate push into recurring revenue streams.
The Industrial Technologies and Services (ITS) segment posted modest organic growth, with compressor and vacuum/blower lines showing strength, especially in Americas and Asia Pacific. Precision and Science Technologies (PST) revenue grew 17% YoY, largely on M&A, with organic orders dampened by tough comps from prior-year hydrogen projects. Q2 also included non-cash impairments tied to ILC Dover and high-pressure solutions, but management stressed these do not alter underlying operations or the long-term life sciences thesis.
- Aftermarket Share Rises: Recurring revenue initiatives lift aftermarket to 37% of total, up 100 bps YoY.
- ITS Regional Strength: Americas and Asia Pacific drive order momentum, with China returning to organic growth.
- PST Margin Progression: Margin expands 40 bps sequentially, up 190 bps over two quarters, aided by integration and product innovation.
Free cash flow for Q2 was $210 million, down YoY due to bond interest timing, but year-to-date FCF is up 13%. Liquidity stands at $3.9 billion, with leverage improving to 1.7x, supporting continued M&A and share repurchases.
Executive Commentary
"With first half organic order growth of low single digits, a book-to-bill of 1.06 times, and a total backlog increasing by 16% since the end of 2024, we remain confident in our full year outlook. We continue to focus on controlling what we can control, staying agile and leveraging IRX in what remains a very dynamic environment."
Vicente Renal, Chairman and CEO
"The year-over-year decline in adjusted EBITDA margin was driven primarily by the flow-through on organic volume declines, as expected, the dilutive impact from recently acquired businesses, the dilutive impact of tariff pricing matching tariff costs one-for-one, and continued targeted investments to drive organic growth."
Vic Kinney, Chief Financial Officer
Strategic Positioning
1. M&A Flywheel and Platform Expansion
Ingersoll Rand’s disciplined M&A engine remains central, with 11 deals closed YTD totaling $200 million in annualized revenue at a 9.5x pre-synergy EBITDA multiple. The company now has eight additional deals under LOI. About 90% of transactions are sole-sourced, often from family-owned targets, supporting niche platform building and technology acquisition.
2. Life Sciences Platform Build-Out
The acquisition of Leeds Fluid marks IR’s first step in constructing a dedicated life sciences platform, bringing advanced peristaltic pump technology and expanding reach in Asia. Management expects bolt-ons to compound value, with a focus on niche applications such as powder containment and high-potency APIs via ILC Dover.
3. Recurring Revenue and Aftermarket Penetration
Aftermarket revenue growth remains a strategic lever, with recurring service programs like AeroProtect driving customer retention and margin stability. The company’s multi-brand, multi-channel approach is designed to maximize installed base monetization and recurring sales.
4. Innovation and Energy Efficiency
Product launches such as the Compare Ultima compressor (14% energy efficiency gain) and EVO series electric diaphragm pump (15% efficiency improvement) underscore IR’s focus on sustainability and technological differentiation. These innovations support both organic growth and margin defense in competitive end markets.
5. Geographic and End-Market Diversification
Order growth in EMEA, APAC, and renewed momentum in China highlight IR’s ability to find pockets of demand despite regional volatility. End-market diversity, including water infrastructure and clean energy, provides ballast against cyclicality in industrial capital spending.
Key Considerations
This quarter’s results reflect Ingersoll Rand’s ability to both defend its core and seed long-term growth through targeted M&A and recurring revenue expansion. The company’s execution on integration, margin management, and innovation will remain under scrutiny as macro and tariff uncertainties persist.
Key Considerations:
- Backlog Strength Underpins Revenue Visibility: Elevated backlog and sustained book-to-bill above one support second-half and 2026 revenue confidence.
- Disciplined M&A Remains Priority: Capital allocation is squarely focused on bolt-ons and platform expansion, with share buybacks as a secondary lever.
- Aftermarket and Recurring Revenue Mix: Growth in service and aftermarket helps insulate margins from equipment cyclicality and pricing pressure.
- Tariff and Regulatory Fluidity: Ongoing tariff negotiations and government incentives (like the Build Back Better Act) are delaying customer decision-making and project conversion.
- Life Sciences Platform Execution: Success in scaling niche life sciences offerings will hinge on bolt-on integration and demand in fast-evolving pharma and biotech verticals.
Risks
Tariff unpredictability, delayed customer decision cycles, and macroeconomic headwinds remain significant variables for both volume and pricing in the second half. Integration risk in life sciences and potential for further impairments on acquired assets could pressure returns if market or customer assumptions shift. Management’s precautionary guidance reflects these uncertainties, especially in North America and capital equipment markets.
Forward Outlook
For Q3 and the remainder of 2025, Ingersoll Rand guided to:
- Raised full-year revenue, adjusted EBITDA, and EPS guidance, with EBITDA midpoint now at $2.13 billion.
- Adjusted tax rate of approximately 23%, net insurance expense of $220 million, and capex at 2% of revenue.
For full-year 2025, management increased guidance and highlighted:
- Organic revenue guidance trimmed solely due to reduced tariff pricing, with no impact on EBITDA or EPS.
- Assumptions of stable book-to-bill, robust backlog, and cautious volume outlook reflecting tariff and macro uncertainty.
Management emphasized that order momentum, strong backlog, and robust pipeline of M&A deals provide a buffer against external shocks, while recurring revenue and integration initiatives are expected to drive sequential margin improvement in the second half.
Takeaways
Ingersoll Rand’s Q2 showcased a resilient business model, with backlog and M&A activity providing revenue visibility and strategic flexibility.
- Backlog and Book-to-Bill Support Confidence: Management’s raised guidance is grounded in backlog strength and continued order momentum, especially in long-cycle projects.
- Disciplined Capital Deployment: The company’s M&A flywheel, focused on bolt-ons and niche platforms, is delivering scale and diversification without compromising balance sheet strength.
- Watch for Integration and Recurring Revenue Progress: Investors should monitor execution in life sciences, aftermarket expansion, and margin progression as key indicators of sustainable value creation.
Conclusion
Ingersoll Rand’s Q2 results reflect a business executing on both organic and inorganic levers, with robust backlog and disciplined capital allocation supporting a raised outlook. The focus on recurring revenue, innovation, and geographic diversification positions the company to weather macro headwinds and capitalize on long-term growth opportunities.
Industry Read-Through
Ingersoll Rand’s backlog-driven visibility and M&A discipline signal that industrials with strong balance sheets and integration playbooks can sustain growth even as capital equipment cycles soften. The focus on recurring revenue and aftermarket expansion is a template for margin defense across the sector. Tariff and regulatory fluidity are delaying investment decisions industry-wide, but companies with robust service models and geographic reach are best positioned to adapt. Watch for continued consolidation and bolt-on activity as a key theme in industrials and life sciences platforms.